Therapeutic Solutions International
Develops "NanoStilbene" Nanoparticle
Formulation of Pterostilbene
Patented Augmenter of Cancer Immunotherapy Successfully
Manufactured
Oceanside,
CA -- March 05,
2018
--
InvestorsHub NewsWire -- Therapeutics
Solutions International, Inc., (OTC PINK: TSOI)
announced
today successful production
of a stable nanoemulsion of pterostilbene from ingredients
Generally Regarded as Safe (GRAS). The nanoemulsion, which is a
form of pterostilbene containing nanoparticles, is covered for use
in cancer immunotherapy under the Company's issued
U.S.
Patent No.: 9,682,047. Pterostilbene is
the active ingredient in the Company's patented
ProJuvenol product.
Pterostilbene,
a more
potent analogue of resveratrol, is extracted from many
plants, and has been reported
by others to possess ability to prevent cancer as well as to slow
its growth. A freely available summary of scientific literature on
pterostilbene is available at the following link http://www.projuvenol.com/lit/.
Unfortunately,
the poor
solubility and stability of pterostilbene has
strictly restrained its
applications. As a good protection and oral delivery system, an
optimal nanoemulsion for pterostilbene was developed by using a low
- energy emulsification method.
"Having
verified
nanoparticle lengths
of the pterostilbene in the 100nm (nanometer) range
we are
excited to now scale-up our manufacturing process for
commercialization. To put this in
perspective the thickness of a
single human
hair
measures
approximately 75,000 nm
across,
meaning 750 of our nanoparticles lined up side by side would fit in
the diameter of a human hair" said
Thomas
Ichim, PhD, Director
of
Therapeutic Solutions International. "In our opinion,
the small size,
combined with the stability of the formulation, positions
our NanoStilbene
product
as second-to-none in terms of effectively delivering the
pterostilbene compound for a variety of uses."
"The product derived
from the '047 patent is currently being called
"NanoStilbene". This
nanoemulsion
droplet
of nanoparticle pterostilbene is free from air,
light, and hard environment; therefore, as a delivery system,
nanoemulsion can not only improve the bioavailability of
pterostilbene but also protect it from oxidation and hydrolysis,
while it possesses an ability of sustained release at the same
time. We hope to announce
soon the availability of this product in a future
release" added
Tim G
Dixon, CEO of Therapeutic
Solutions International.
About Therapeutic Solutions International,
Inc.
The
Company's corporate website is www.therapeuticsolutionsint.com. Our
new products can be viewed on www.projuvenol.com and products can
be ordered at www.youcanordernow.com.
These
Supplement products have not been evaluated by the United States
Food and Drug Administration. These products are not intended to
diagnose, treat, cure or prevent any diseases.
Safe
Harbor Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT INFORMATION
Therapeutic Solutions
International, Inc.
ir@tsoimail.com